Evolving trends in lung cancer: epidemiology, diagnosis, and management
R Deshpand, M Chandra, A Rauthan - Indian Journal of Cancer, 2022 - journals.lww.com
Lung cancer is one of the deadliest cancers globally and accounts for most of the cancer-
related deaths in India. Comprehensive data on lung cancer in India are lacking. This review …
related deaths in India. Comprehensive data on lung cancer in India are lacking. This review …
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective
Background Immunotherapy with checkpoint inhibitor programmed death-1 (PD-1) and
programmed death-ligand 1 (PD-L1) antibodies targeting the cellular immune checkpoints is …
programmed death-ligand 1 (PD-L1) antibodies targeting the cellular immune checkpoints is …
Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer
M Kumar, B Guleria, S Swamy, S Soni - Lung India, 2020 - journals.lww.com
Objectives: The aim of this study is to evaluate the incidence of programmed cell death-
ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) cases and its correlation …
ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) cases and its correlation …
Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective
A Aggarwal, S Sharma, Z Brar, V Kumar… - … -Research and Practice, 2024 - Elsevier
Background The understanding of molecular mechanisms involved in non-small cell lung
carcinoma (NSCLC) has revolutionized significantly in the recent years. These have helped …
carcinoma (NSCLC) has revolutionized significantly in the recent years. These have helped …
PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center
S Kilaru, SS Panda, L Moharana, D Mohapatra… - Journal of the Egyptian …, 2024 - Springer
Background Targeted therapies against programmed death ligand-1 (PD-L1) in non-small
cell lung cancer (NSCLC) have revolutionized the management in recent years. There is …
cell lung cancer (NSCLC) have revolutionized the management in recent years. There is …
Study of PD-L1 Expression in Tumours Based on Site and Histology of Tumour–The Experience of a Tertiary Referral Laboratory
V Pant, M Harlalka - Asian Pacific Journal of Cancer Biology, 2023 - waocp.com
Background: PD-L1 IHC test is used as a predictive biomarker using FDA-approved assays
to select patients likely to benefit from immunotherapy in several advanced-stage tumors …
to select patients likely to benefit from immunotherapy in several advanced-stage tumors …
[HTML][HTML] The Prevalence of Programmed Death Ligand-1 (PD-L1) Expression in Non-Small Cell Lung Cancer: An Experience From Tertiary Care Hospital
A Mehta, LP VP, L Teja, K Pillai - Cureus, 2024 - pmc.ncbi.nlm.nih.gov
Background: The prevalence of programmed cell death ligand-1 (PD-L1) expression in non-
small cell lung cancer (NSCLC) within unselected populations remains a research topic …
small cell lung cancer (NSCLC) within unselected populations remains a research topic …
Assessment of Programmed Cell Death Ligand-1 Expression in Non-small Cell Lung Carcinomas by Immunohistochemistry
S Mani, A Lakshmanan, A Subramanyan - Apollo Medicine, 2024 - journals.sagepub.com
Background: Non-small cell lung carcinomas (NSCLCs) expressing programmed cell death
ligand-1 (PD-L1), a transmembrane protein, are more likely to respond to immunotherapy …
ligand-1 (PD-L1), a transmembrane protein, are more likely to respond to immunotherapy …
Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients
S Kumar, M Pandey, IA Mir, A Mukhopadhyay… - Human Cell, 2022 - Springer
The presence of membranous immunopositivity of programmed death-ligand 1 (PD-L1) in
tumors serves as a key determinant of response to immune checkpoint inhibitors. However …
tumors serves as a key determinant of response to immune checkpoint inhibitors. However …
[PDF][PDF] ZZZ OXQJLQGLD FRP
R VL, H DOO - 2020 - researchgate.net
Objectives: The aim of this study is to evaluate the incidence of programmed cell death‑
ligand 1 (PD‑L1) expression in non‑small cell lung cancer (NSCLC) cases and its correlation …
ligand 1 (PD‑L1) expression in non‑small cell lung cancer (NSCLC) cases and its correlation …